M ortality and morbidity in patients with cortical infarcts (CI) are generally greater than those with the lacunar variety.' '3A contributory cause of early death in CI is believed to be edema around the ischemic lesion, leading to transtentorial herniation.45 In an attempt to reduce the damaging effect of cerebral edema, various forms of treatment, in particular steroids and hyperosmolar agents, have been advocated in the past. However, clinical trials now indicate that steroid treatment has no place in the management of acute ischemic strokes.6,7 Intravenous treatment with glycerol, a hyperosmolar agent, has been shown in animal studies to reduce edema around cerebral infarcts8'9 and improve cerebral blood flow in the ischemic region.10 A beneficial effect on cerebral metabolism is also claimed." Earlier clinical studies of such treatment have shown conflicting results in the outcome of ischemic strokes.12-18 However, most of these studies lacked confirmation of infarct subtypes with computed tomography (CT) or autopsy, were poorly controlled, and entailed small patient numbers, a long delay before commencing treatment, or a short follow-up. A recent double-blind, randomized trial with 173 patients concluded that glycerol reduced the mortality in the first week of ischemic strokes. ' *In the glycerol group deaths were attributed to brain-stem herniation in 7 (only 3 of whom were alert at entry), pneumonia in 2, septicemia in 2, myocardial infarction in 3, and unknown and other causes in 2. For the placebo group, corresponding figures were 8 (3 were alert at entry), 5, 4, 0, and 0, respectively. Figures in parentheses refer to patients who developed gross hemoglobinuria, warranting discontinuation of trial medication.
tion was commenced within 48 hours of symptoms. Active treatment was 500 mL of 10% glycerol in physiological saline, and placebo consisted of 500 mL of physiological saline; each was infused intravenously over 4 hours on 6 consecutive days.
Analysis and statistical methods. This study was run concurrently with a larger trial to assess the possible value of intravenous glycerol in patients with acute spontaneous supratentorial intracerebral hemorrhage conducted for a 2-year period. Hemolysis (generally subclinical) was the only side effect noted. Table 2 shows the respective numbers of patients in whom either treatment was withdrawn because of perceived gross hemoglobinuria. Our investigation found no clinically or statistically significant difference between the glycerol-and placebotreated patients with respect to mortality and neurological and long-term scores, which is in contrast to the findings reported by Bayer and colleagues. 19 In the latter study, however, CT was not undertaken routinely to exclude hemorrhage (a shortcoming admitted by the authors), patients were not stratified according to prognosis, lacunar infarcts were not considered separately, and the most serious cases (in whom death seemed imminent) were excluded. In addition, they analyzed absolute neurological scores, not differences from pretreatment/initial values, and for some reason, patients who died were assigned the lowest score for survivors rather than zero.
Although our study did not reveal any definite neurological benefit after glycerol treatment, the following provisos are nevertheless relevant. First, our trial had insufficient patient numbers to evaluate subtle or small benefits or to realistically detect differences confined to the coma and/or semicoma subgroups. Second, the timing of glycerol intervention may have been too delayed. Nevertheless, the mean interval of 33 hours between the onset of symptoms and treatment of our patients was much shorter than in several previous studies (up to 1 week).12"13,15 Although a delay in treatment may not be as critical as in thrombolytic therapy, it might still be too long in relation to the 6 to 8 hours within which reestablishment of cerebral perfusion could lead to optimum salvage of the ischemic penumbra. Finally, there are suggestions that higher glycerol concentrations should be achieved to produce clinically significant osmotic effects. 26 However, increased glycerol infusion rates are likely to be associated with substantially increased risks, which include hyperglycemia, hyperosmolality, and convulsions as well as intravascular hemolysis and possible renal failure. [27] [28] [29] Assuming that glycerol can indeed exert a cerebral osmotherapeutic effect, it is likely to depend on the osmotic gradient developed between plasma and brain tissue rather than any absolute increase in osmolality. As glycerol crosses the blood-brain barrier, the prevailing osmotic gradient must therefore depend on how quickly respective plasma concentrations in these tissues increase. Consistent with this concept, the rate of increase in plasma glycerol concentration rather than the absolute concentration was found to be the more important determinant of intracranial pressure response.30 Moreover, the osmotic effect of glycerol infused into plasma may become quickly negated as it is (1) metabolized and/or leaves the circulation and (2) diluted by water from other tissues entering the blood by osmosis.
As in nearly all previous clinical studies of intravenous glycerol in acute stroke, measuring changes in plasma osmolality was not part of our protocol. However, soon after initiation of this and a related study in patients with acute supratentorial hemorrhage involving an identical dosing regimen,23 we had occasion to report on the mechanism of glycerol-induced hemolysis.28 In a small cohort of these cases (seven receiving glycerol and four control subjects), plasma osmolality changes in peripheral venous blood were measured but not published. When treatment infusions were about to cease, respective mean+SD increments in plasma osmolality were only 9.4+8.2 and 8.5±4.7 mOsm/L. Thus, like others18 we were unable to confirm any important enduring impact of glycerol on osmolality, and the absolute increments in the treated and control groups were of the same order as those reported after oral glycerol by Rottenberg et al,31 but they had no control subjects. Nevertheless, a much more rapid but transient effect on osmolality cannot be excluded. Theoretically, evaluation of this issue requires selective catheterization of central blood vessels and concurrent frequent blood sampling during the initiation of treatment infusions. Similar considerations may also apply to assessing the postulated rapid impact of plasma osmolality changes on intravascular hemolysis. 28, 29 In contrast to intravenous dosing with glycerol, large oral doses can achieve much higher plasma concentrations without inducing hemolysis.32 It has been suggested that this paradox could be due to the very gradual absorption of glycerol into the large blood volume flowing through the mesenteric circulation.33 Thus, correspondingly exposed red cells may never be submitted to osmotic gradients sufficient to cause lysis on mixing successively with splenic, hepatic, and inferior vena caval blood. Notwithstanding the very high eventual plasma concentrations ensuing after oral dosing, alleviation of intracranial hypertension is very rapid (within 1 hour) and transient.3031 Whatever the mechanism of this effect, it is unclear whether the resulting blood-brain osmotic gradients are comparable to those achieved with parenteral treatment. Furthermore, large oral doses of glycerol may well carry an unacceptable risk of aspiration in patients with acute stroke. As an alternative means of limiting hemolytic effects, the Japanese have pioneered the use of intravenous glycerol containing small amounts of fructose, but this approach needs further assessment. 29, 34, 35 The possible beneficial effect of glycerol on indexes of daily living among survivors is of particular interest, because it was in marked contrast to the results obtained by Bayer's group. 19 However, after such treatment for presumed middle cerebral artery infarction, other investigators have also described a similar (although transient) benefit in terms of functional recovery among moderately disabled patients.'6 Regrettably, like most trials conducted over a decade ago, CT confirmation of the diagnosis was not obtained. Moreover, despite having much smaller patient numbers than ours and no stratification according to prognosis, a statistically significant benefit was observed. The predominantly left-sided lesions among their patients given placebo suggest that the latter were more likely than the glycerol group to have dominant hemisphere involvement, which may have biased rehabilitation scores in favor of glycerol treatment. In contrast, in our patient sample there was a contrary trend (ie, greater proportion of left-sided lesions in the glycerol group; Table 1 ) favoring placebo.
In conclusion, intravenous glycerol therapy as used in this group of patients with acute CI had no discernible benefit in terms of long-term overall outcome or neurological recovery. However, among survivors, there was a suspicion of benefit in terms of overall activity of daily living.
